3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
16
Rectal Neoplasms
4
Colonic Neoplasms
4
Stomach Neoplasms
3
Neoplasm Metastasis
3
Neoplasms
2
Biliary Tract Neoplasms
2
Sarcoma, Ewing
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Metastatic Gastric Adenocarcinoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastric Cancer Adenocarcinoma Metastatic
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Dihydropyrimidine Dehydrogenase Deficiency
1
Desmoid Tumors
1
Craniopharyngioma
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced/Metastatic Solid Tumors
1
Advanced Solid Tumors
1
Adenomatous Polyposis Coli
1
Adenocarcinoma Of Esophagus
1
Interventions
Cyclophosphamide
23
venetoclax
17
Dexamethasone
16
pembrolizumab
15
fludarabine
15
Cytarabine
13
pomalidomide
8
Rituximab
8
Gemcitabine
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
selinexor
6
Paclitaxel
6
Injections
6
Immunotherapy, Adoptive
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Oxaliplatin
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
trifluridine tipiracil drug combination
×
Clear all
NCT05476796
2024-10-24
LOGICAN
UNICANCER
Phase 2
Recruiting
118 enrolled